bluuebunny/crossref_metadata_2025_split huggingface dataset:
Bone marrow transplantation in childhood leukemia using reverse isolation techniques
Authors: Ogden Angela Kent , Steuber C. Philip , Mahoney Donald H. , Fernbach Donald J. 
Published: February 2007

AbstractBetween 1979 and 1986, 29 pediatric patients underwent bone marrow transplantation at Texas Children's Hospital using routine reverse isolation. Laminar air flow rooms, prophylactic antibiotics, and gut sterilization were not utilized. The diagnoses included acute lymphocytic leukemia (ALL) (16 patients), acute nonlymphocytic leukemia (ANLL) (10 patients), and chronic myelogenous leulemia (CML) (three patients). All patients had fever during hospitalization. There were 11 episodes of bacteremia in seven patients giving a bacteremia rate of 37.9%. Moderate‐to‐severe (grade II–IV) acute graft‐versus‐host disease (GVHD) was seen in eight patients (27.6%). The incidence of infection and GVHD during the first 100 days post‐transplantation is comparable to published reports from centers utilizing rigid isolation and sterilization of the gut. It is suggested that bone marrow transplantation may be done using standard reverse isolation techniques without increasing the morbidity or mortality of the procedure.
Undifferentiated acute leukemia and lineage infidelity (difficulties in classification and management)
Authors: Delaat Cynthia A. , Files Beatrice , Harris Richard E. , Neudorf Steven , Lampkin Beatrice C. 
Published: February 2007

AbstractThe acute leukemias have been considered to represent a clonal expansion of a malignant transformed hematopoietic progenitor cell with adherence to either the myeloid or lymphoid lineage—“lineage fidelity.” Lineage fidelity has been challenged by the demonstration of lineage switching or mixed‐lineage leukemias. We describe a 7 year old male who presented with undifferentiated acute leukemia and nasopharyngeal and cervical masses. His blasts had the morphologic appearance of myeloblasts (FAB M1) and were positive solely for the myeloid antigen CD15. He entered a complete remission (CR) with acute nonlymphocytic leukemia therapy. At first relapse he had evidence of mixed‐lineage leukemia with B‐cell lymphoid and myeloid phenotypes. He again relapsed from a second CR with Burkitt‐cell leukemia. Cytogenetic findings showed a consistent 14q+,17p+ abnormality in the blasts and nasopharyngeal mass. The t(8;14) associated with Burkitt's lymphoma was found in the mass tissue only following passage in the nude mouse.Our patient demonstrates that limitations still exist in our ability to classify acute leukemia. That leukemic transformation occurred in a multipotential progenitor cell leading to undifferentiated leukemia at diagnosis and/or that chemotherapy can influence the genetic programs of leukemic cells leading to the evidence of mixed‐lineage leukemia and lineage switching is supported.
Systemic administration of radionuclides in neuroblastoma as planned radiotherapeutic intervention
Authors: Lashford L. S. , Clarke J. , Kemshead J. T. 
Published: February 2007

AbstractTargeted radiotherapy, using systemically administered radionuclides, is an exciting proposition for the treatment of disseminated disease. In neuroblastoma, two groups of compounds have been developed as radiation delivery systems: monoclonal antibodies, exemplified by UJ13A, and the small‐molecular‐weight radio‐pharmaceutical meta‐Iodobenzylguanidene (mIBG).
Rhabdomyosarcoma with heterologous cartilage of the uterine cervix: A clinicopathologic and immunohistochemical study of an aggressive neoplasm in a young female
Authors: Perrone Theresa , Carson Linda F. , Dehner Louis P. 
Published: February 2007

AbstractThis report concerns a 20‐year‐old female who had a F.I.G.O. stage I rhabdomyosarcoma (sarcoma botryoides) of the cervix with a predominant embryonal pattern and heterologous cartilage that pursued an aggressive course despite surgery and chemotherapy. The patient had a pelvic recurrence, developed pulmonary metastases 15 months after diagnosis, and died 6 months later. Despite some previously published favorable prognostic assessments about this unique variant of cervical rhabdomyosarcoma, our limited experience would interject a note of caution, especially in the presence of a focal alveolar pattern and invasion of lymphatics in the cervix.
Prognostic factors for patients with diffuse large cell or immunoblastic non‐Hodgkin's lymphomas: Experience of the non‐Hodgkin's lymphoma pathologic classification project
Authors: Simon Richard , Durrleman Sylvain , Hoppe Richard T. , Bonadonna Gianni , Bloomfield Clara D. , Rudders Richard A. , Cheson Bruce D. , Berard Costan W. 
Published: February 2007

AbstractPrognostic factors for long‐term survival of 312 patients with diffuse large cell or immunoblastic non‐Hodgkin's lymphoma are presented based on analysis of the multi‐institution clinicopathologic study sponsored by the National Cancer Institute. At the time of analysis, 75% of the patients had died and the median follow‐up for patients still alive was 11 years. The distribution of Ann Arbor stages was 21% stage 1, 32% stage 11, 17% stage III, and 30% stage IV. Factors of prognostic significance for survival included age, stage, histologic subtype, presence of B symptoms, size of the largest lesion, number of extra‐lymphoid organs involved, and extent of lymphatic involvement. Recursive partitioning analysis suggested a prognostic classification system based on stage, age, size of the largest lesion, and presence of mediastinal involvement. Stage I patient <50 years of age had a 10 year survival rate of 65% compared to 36% for older stage I patients. Stage II patients <65 years old without bulky lesions or mediastinal involvement had a 10 year survival rate of 45% compared to 10% for the poorer risk stage II patients. Although statistically significant prognostic factors were identified for the stage III/IV patients, they were not strong discriminants of 5–10 year survival rate. Because of the correlation among potential prognostic factors, there is no uniquely best classification system. Reasons for discrepancies among reported prognostic factor analyses are discussed, and a prognostic grouping that synthesizes our results with those of others is proposed.
Radiation therapy in the management of langerhans cell histiocytosis
Authors: Selch Michael T. , Parker Robert G. 
Published: February 2007

AbstractTwenty‐two patients with Langerhans cell histiocytosis (LCH) were managed in the UCLA Department of Radiation Oncology from 1974 to 1987. Their median age was 17 years (range 1–42 years) and median followup 4.5 years (range 1–13 years). Fourteen patients had disease localized to a bone (13) or a soft tissue (one). Eight patients had LCH involving multiple bones (3) or soft tissues plus bones (5). Nine of 10 patients less than 19 years old had disease confined to bone(s) compared to 7 of 12 older patients. Fifty‐six sites of LCH (40 bone, 16 soft tissue) were irradiated. Pediatric patients received therapy to 15 sites (14 bone, 1 soft tissue) and adults 41 sites (26 bone, 15 soft tissue). Median dose for bone lesions was 900 cGy (range 600–1,500) and for soft tissue 1,500 cGy (range 600–2,600). Local control was achieved in 46 of 56 sites (82%). Control rates for bone and soft tissue lesions were 35 of 40 (88%) and 11 of 16 (69%), respectively. Fifteen of 15 sites in pediatric patients were controlled compared to 29 of 41 (72%) in adults. Ten sites (18%) recurred 10 months to 4 years after irradiation. Recurrences were in‐field and noted only in adults with involvement of multiple soft tissues plus bones. All recurrent soft tissue lesions had been treated with orthovoltage. Five patients developed new foci of LCH subsequent to irradiation. Four of these patients had disease involving soft tissues and bones. One patient with progressive LCH initially presented with a single bone lesion. The acute and chronic effects of radiation therapy were minimal. One patient suffered transient enlargement of adenopathy. An elevated serum TSH level was detected 9 years after irradiation of a cervical vertebra in another patient.
Epidemiological and familial aspects of hepatoblastoma
Authors: Hartley A. L. , Birch J. M. , Kelsey A. M. , Jones P. H. Morris , Harris M. , Blair V. 
Published: February 2007

AbstractData on the 20 cases of hepatoblastoma registered with the Manchester Children's Tumour Registry between 1954 and 1988 are presented. The cases represent about 0.6% of childhood malignancies and show a male: female ratio of 2.3:1. Age at presentation was almost always under 2 1/2 years. Cancer rates in close relatives were not significantly different from those expected. One family was confirmed as having Gardner syndrome, but the presence of other syndromes e.g., Beckwith‐Wiedemann, could not be reliably detected in this retrospective series. The need to take an extensive pedigree and for clinical examination of other family members at the time of the child's diagnosis is emphasized.
Neuropsychologic and ct examinations in leukemic patients surviving 10 or more years
Authors: Schuler D. , Bakos M. , Borsi J. , Gacsály I. , Kálmánchey R. , Kardos G. , Koós R. , Nagy C. S. , Révész T. , Somló P. , Gebauer E. 
Published: February 2007

AbstractLong‐term survivors of childhood leukemia were studied to determine their neuropsychologic status. All had had cranial irradiation 10 or more years before. The results were1. The IQ and academic performance of 56 cured leukemic patients show no significant difference from the normal population.2. More exact neuropsychological tests (attention, reaction time, visual‐motor coordination, memory) reveal important deficits.3. The frequency of CT aberrations in 33 study patients was 45% and showed no correlation with either the IQ or other neuropsychological results.
Familial phaeochromocytoma: Successful treatment with 131I‐MIBG
Authors: Goncalves Eduardo , Ninane Jacques , Wese François‐Xavier , Leonet Jacqueline , Piret Louis , Cornu Guy , De Meyer Roger 
Published: February 2007

AbstractWe report the case of a family in which the mother died of hypertensive encephalopathy following the relapse of a phaeochromocytoma. Two of her children are still alive. Both children had malignant phaeochromocytomas that have been treated by surgery and 131I‐MIBG. The first child presented with phaeochromocytoma of the right suprarenal gland at the age of 7 years. Surgery was performed. At the age of 14 years, he developed a tumour of the left suprarenal gland and two pulmonary metastases demonstrated by 131‐MIBG. The three tumours were removed, but new lesions occurred. The boy then was treated with 200 mCi (7,400 MBq) of 131‐MIBG given twice, and is now free of disease more than 2 years after treatment. His sister presented at the age of 12 years with phaeochromocytoma of the left suprarenal gland, the only lesion recognized by 131I‐MIBG. The tumour was removed, but 5 months later, she developed phaeochromocytoma in the right suprarenal gland. She was treated with 200 mCi (7,400 MBq) of 131I‐MIBG and surgery was performed 6 months later. Histology of the suprarenal gland could not demonstrate the persistence of phaeochromocytoma cells. The child is now free of disease more than 2 years after treatment.
Intracellular ribonucleotide pools of lymphoblastic leukemic cells in untreated and relapsed all children
Authors: Kawasaki Hajime , Hori Hiroki , Higashigawa Masamune , Ookubo Toshiki , Sakurai Minoru 
Published: February 2007

AbstractIntracellular ribonucleotide pools were analyzed by HPLC with leukemic blasts obtained from 20 children, including 13 untreated ALL, 5 relapsed ALL, and 2 lymphomas with hematological relapse.Nucleotide pools were, in general, found more expanded among relapsed cases. Also, the larger mono and diphosphate ribonucleotide levels found in relapsed cells, for instance adenine nucleotide pools, were significantly larger among the relapsed patients, as measured 216.97 ± 53.30 nmol/108 cells, in contrast to 109.70 ± 39.54 nmol/108 cells with untreated children (p<0.005). Furthermore, AMP and ADP occupied only 18% of the total adenine pool in untreated children, but 34% in relapsed children. The similar pattern of nucleotide pools was observed in guanine, cytidine, and uridine nucleotide pools.Inosine mono phosphates were measured 5.07 ± 6.02 nmol/108 cells with untreated ALL, and 3.55 ± 1.44 nmol/108 cells with relapsed ALL, but thymidine mono phosphates, as a key pyrimidine nucleotide of salvage pathway, were larger (p<0.01) among with relapsed patients measuring 31.47 ± 8.11 nmol/108 cells as compared with that of untreated ALL, 11.19 ± 12.84 nmol/108 cells.The present results may suggest that there is a difference in nucleotide metabolism between untreated and relapsed leukemic cells, and nucleotide profiles provide more accurate information of leukemia chemotherapy.
Sudden neurologic death after intrathecal methotrexate
Authors: Shore T. , Barnett M. J. , Phillips G. L. 
Published: February 2007

AbstractMethotrexate leukoencephalopathy is a chronic syndrome of ataxia and confusion which may progress to seizures, coma, and death. We report a fatal case of this syndrome in a patient who displayed no evidence of the typical prodrome of neurologic symptoms or signs. This patient suffered brain death after receiving 11 doses of intrathecal methotrexate for leukemic meningitis. Since leukoencephalopathy was not clinically suspected, this case underscores the need for a test that would reliably monitor central nervous system toxicity due to intrathecal therapy.
Cytotoxic drug‐induced fever: A report on procarbazine‐induced hyperpyrexia
Authors: Akyol Hatice , Sarialioglu Faik , BüyükpamukcCu Münevver , Akyüz Canan 
Published: February 2007

AbstractA case of hyperpyrexia induced by procarbazine in a child with Hodgkin's disease, neurofibromatosis, and pectus excavatum deformity is presented. After the diagnosis of stage IIIS Hodgkin's disease, combined COPP chemotherapy was initiated. One week later she presented with high fever. After a diagnosis of infection was made, chemotherapy was stopped and antibiotics were given. Nearly the same picture recurred three times after reinstituting chemotherapy. On the fourth occasion, the patient had to be hospitalized because of hyperpyrexia and arrhythmia. There was no obvious reason for fever, and cytotoxic‐induced fever was considered. The drugs were given one at a time. When a test dose (10 mg) of procarbazine was given, she developed a high fever with severe nausea and vomiting. The reaction was controlled by antihistaminics and steroids. To our knowledge this is the second report on hyperpyrexia due to procarbazine administration.
Phase II trial of etoposide and cis‐diaminodichloro‐platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and leukemia group B (CALGB) study 8353
Authors: Rybak Mary Ellen , McCarroll Kathleen , Kaplan Richard J. , Propert Kathleen J. , Budman Daniel R. , Gottlieb Arlan J. 
Published: February 2007

AbstractA phase II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed Hodgkin's disease (HD) to assess the activity of the combination of etoposide and cis‐platin. Twenty‐seven patients were entered; 22 were evaluated for this report. Treatment consisted of etoposide (VP‐16), 80 mg/m2 IV over 1 hour and cis‐platin, 20 mg/m2IV over 1/2‐1 hour; both agents were given daily for 5 days and repeated every 21 days. All patients had received at least 2 prior chemotherapy regimens, had measurable disease, and most (86%) had a performance status of 0‐1. In the 22 evaluable patients, there were 4 complete responses (18%) and 4 partial responses, for an overall response rate of 36% (95% Cl: 17.2%, 59.3%). Response duration was from 2.1 to 31 months. Significant toxicity was observed with this regimen. Ten patients (45%) had leukopenia <1,000/μl, and 11 patients (50%) had thrombocytopenia <25,000/μl. Serum creatinine levels reached >2.0 in 14% of patients. Seven patients (32%) had severe nausea and vomiting. VP‐16, cis‐platin appears to be an active combination in HD; however, their combined activity is only marginally better than reported single‐agent activity for VP‐16 in the doses and schedule used. Further studies of related combinations in HD are currently under evaluation by the CALGB.
2′ deoxycoformycin (pentostatin) for refractory non‐Hodgkin's lymphoma: A calgb phase II study
Authors: Duggan D. B. , Anderson J. R. , Dillman R. , Case D. , Gottlieb A. J. 
Published: February 2007

AbstractSeventy‐six eligible patients with relapsed or refractory non‐Hodgkin's lymphoma (NHL) were treated with 2′‐deoxycoformycin (pentostatin) at a dose of 4 mg/m2 intravenously weekly for three weeks and then every other week for a minimum of five total treatments. All patients had measurable disease, near normal hematologic, renal, and hepatic function, and a performance status of 0 or 1. Severe hematologic toxicity was observed in 13% of patients; severe renal or neurologic toxicity was observed in less than 5% of patients. There were no treatment‐related deaths. Objective therapeutic responses were seen in 16% of patients (five complete response [CR] and seven partial response [PR]). However, in three of the patients achieving CR and one patient achieving PR, dexamethasone was employed as an anti‐emetic, making the response of these patients to pentostatin difficult to evaluate. There were eight responses (3 CR) in patients with diffuse histologies and four responses (2 CR) in patients with nodular or mixed histologies. Three responses were in patients with a T‐cell phenotype. Three of five patients with diffuse well‐differentiated lymphoma (IWF A) responded. We conclude that 2′ deoxycoformycin is only minimally active at this dose and schedule against refractory or relapsed NHL. The possibility that low grade B‐ and T‐cell malignancies are more sensitive to 2′ deoxycoformycin deserves further investigation.
Turcot's syndrome with intestinal lymphoma in a child: An unusual case of triple tumor
Authors: Aricó Maurizio , Parigi Gian Battista , Locatelli Davide , Bragheri Romano , Lombardi Fabrizio , Zangrandi Adriano 
Published: February 2007

AbstractTurcot's syndrome, the association of brain tumor (usually glioblastoma, medullo‐blastoma, or astrocytoma) and colonic polyps, is a very rare condition of which about 20 cases have been reported. It has been described only once previously with cancer in a third organ system. In this paper, we report a child affected with colonic polyposis and astrocytoma (i.e., Turcot's syndrome) associated with intestinal non‐Hodgkin's lymphoma.
Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration
Authors: Aricó Maurizio , Nespoli Luigi , Porta Fulvio , Caselli Dèsirèe , Raiteri Emanuela , Burgio G. Roberto 
Published: February 2007

AbstractIn a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life‐threatening, acute encephalopathy with high‐pressure hydrocephalus. Ventriculoperitoneal shunting led to complete reversal of hydrocephalus with progressive disappearance of the acute encephalopathy.
Acute nonlymphocytic leukemia after transient myeloproliferative disorder in a patient with down syndrome
Authors: Barnett P. L. J. , Clark A. C. L. , Garson A. C. M. 
Published: February 2007

AbstractAn infant with Down syndrome (DS) and RH isoimmunization developed transient myeloproliferative disorder (TMD) during the neonatal period. At 16 months she presented with acute nonlymphocytic leukemia (ANLL). Cytogenetic studies during TMD showed trisomy 21 only but new abnormalities emerged during ANLL. She is now in complete remission 5 years after diagnosis. Patients with TMD have either trisomy 21 or mosaic 21 in blood and bone marrow but in phenotypically normal children this cell line disappears with resolution of the TMD. A review of the literature indicates that there are no clinical, hematological, or cytogenetic differences between DS children with TMD who subsequently develop acute leukemia and those who do not. However, the leukemia in the former group may differ in presentation, type, and possibly survival time from other DS children who develop leukemia de novo.
Childhood malignant lymphoma of bone
Authors: Coppes Max J. , Patte Catherine , Couanet Dominique , Caillaud Jean‐Michel , Salloum Emile , Brugières Laurence , Hartmann Olivier , Kalifa Chantal , Bernard Alain , Lemerle Jean 
Published: February 2007

AbstractFrom 1974 to 1987, 450 children with non‐Hodgkins' lymphoma (NHL) were seen at the Institut Gustave Roussy (IGR); 14 children had malignant lymphoma of bone (MLB). Eleven of the 14 were newly diagnosed, whereas three presented in relapse. Nine patients presented with multifocal bone involvement. The median age of these eight girls and six boys was 9.5 years (range 1.25–15 years). Bone pain was present in all patients as the initial symptom. Evaluation included physical examination, routine serum chemistries, complete blood count, chest roentgenography, skeletal survey, radionuclide bone scan, lumbar puncture, bone marrow aspiration, and intravenous pyelography, and/or abdominal ultrasonography. Hypercalcemia was found in six patients. Biopsy was performed in 12 patients, revealing high‐grade lymphoblastic lymphomas in all. In two patients diagnosis was made on cytological examination of bone marrow aspirate. Immunophenotyping in four cases, demonstrated non‐B, non‐T cell origin in three and pre‐B cell origin in one. Three patients were treated prior to 1982 with Cyclophosphamide/Oncovin/Prednisone/ADriamycin (COPAD) and seven patients, seen after 1982, were treated with a modified LSA2L2 protocol (LMT). None of the previously untreated patients received radiotherapy. All patients treated with CO‐PAD have died, whereas four out of seven treated with LMT are alive with a median follow up of 51 months (range 36–82 months). One child treated on a pilot study died. One of the three children seen at relapse is disease‐free with a follow‐up of 98 months after high‐dose chemotherapy followed by autologous bone marrow transplantation (ABMT). Five out of six patients presenting with hypercalcemia have died. Results with LMT are encouraging and together with published results suggest that sufficiently intensive chemotherapy can result in complete remission and cure in MLB. Radiotherapy does not seem to be necessary, avoiding possible serious long‐term effects. Hypercalcemia is a bad prognostic feature.